Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy

Cancer Biomarkers

Volumn 8, Issue 2, 2010, Pages 81-87

  Sarkar, Debansu ^a   Singh, S K ^a   Mandal, Arup K ^a   Agarwal, Mayank M ^a   Mete, Uttam K ^a   Kumar, Santosh ^a   Mavuduru, Ravimohan S ^a   Prasad, Rajendra ^b  

^a Department of Urology   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Castrate resistant prostate cancer; Chromogranin A; docetaxel; Neuroendocrine differentiation

Indexed keywords

ALKALINE PHOSPHATASE; CHROMOGRANIN A; DOCETAXEL; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADD ON THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASTRATION; CHROMOGRANIN A; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052589294     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0198     Document Type: Article

References (28)

1. A. Heidenreich, G. Aus, C.C. Abbou et al., Guidelines on Prostate Cancer: European Association of Urology March 2007 update, p. 97.
2. D.P. Petrylak, C. Tangen, M.H.A. Hussain et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Eng J Med 351 (2004), 1513-1520. (Pubitemid 39315318)
3. I.F. Tannock, R. de Wit, W.R. Berry et al., Docetaxel plus pred-nisone or mitoxantrone plus prednisone for advanced prostate cancer, N Eng J Med 351 (2004), 1502-1512. (Pubitemid 39315317)
4. E.D. Crawford, D.K. Pauler, D.M. Tangen et al., Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (CRPC): Data from Southwest Oncology Group Study S9916, Proc Am Soc Clin Oncol 23 (2004), A4501.
5. M. Rossener, R. de Wit, I.F. Tannock et al., PSA response as surrogate end point for overall survival: analysis of the TAX 327 study comparing the Docetaxel plus prednisolone with mitoxantrone plus prednisolone for advanced prostate cancer, Proc Am Soc Clin Oncol 23 (2005), A4554.
6. N.M. Hoosein, M. Abdul, R. McCabe et al., Clinical significance of elevation of neuroendocrine factors and interleukin-6 in metastatic prostate cancer, Urol Oncol 1 (1995), 245-251.
7. A. Sella, M. Konichezky, D. Flex et al., Low PSA metastatic androgen-independent prostate cancer, Eur Urol 38 (2000), 250-254. (Pubitemid 30665949)
8. A. Berruti, L. Dogliotti, A. Mosca, G. et al., Potential clinical value of circulating chromogranin A in patients with prostate carcinoma, Ann Oncol 12(Suppl 2) (2001), S153-S157. (Pubitemid 33069706)
9. D. Hirano, Y. Okada, S. Minei et al., Neuroendocrine differentiation in CRPC following androgen deprivation therapy, Eur Urol 45 (2004), 586-592. (Pubitemid 38481685)
10. L.J. Deftos, S. Nakada, D.W. Burton et al., Immunoassay and immunohistology studies of chromogranin A as a neuroen-docrine marker in patients with carcinoma of the prostate, Urology 48 (1996), 58-62. (Pubitemid 26255959)
11. R. Ischia, A. Hobisch, R. Bauer et al., Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate, J Urol 163 (2000), 1161-1164.
12. A. Berruti, A. Mosca, M. Tucci et al., Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease, Endocr Relat Cancer 12 (2005), 109-117. (Pubitemid 40477092)
13. M.E. Taplin, D.J. George, S. Halabi et al., Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study, Urology 66 (2005), 386-391. (Pubitemid 41138103)
14. R.J. Cohen, G. Glezerson and Z. Haffejee, Neuro-endocrine cells-a new prognostic parameter in prostate cancer, Br J Urol 68 (1991), 258-262.
15. D.G. Bostwick, J. Qian, A. Pacelli et al., Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival, J Urol 168 (2002), 1204-1211.
16. A. Cabrespine, L. Guy, F. Gachon et al., Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy, J Urol 175 (2006), 1347-1352.
17. N. Vashchenko and P.A. Abrahamsson, Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities, Eur Urol 47 (2005), 147-155. (Pubitemid 40126970)
18. S. Gernone. A. Trabucco, Pagliarulo et al., Use of chro-mogranin A in expression to predict docetaxel response in metastatic hormone refractory prostate cancer. 2008 Genitourinary cancer symposium, A154.
19. A. Berruti, L. Dogliotti, A. Mosca et al., Circulating neuroen-docrine markers in patients with prostate adenocarcinoma, Cancer 88 (2000), 2590-2597. (Pubitemid 30331968)
20. M. Ferrero-Pous, A.M. Hersant, A. Pecking, M. Leroy and M.F. Pichon, Serum chromogranin-A in advanced prostate cancer, BJU Int 88 (2001), 790-796.
21. G. Bubley, J.M. Carducci, W. Dahut et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol 17 (1999), 3461-4367.
22. A.B. Miller, B. Hoogstraten, M. Staquet and A. Winkler, Reporting results of cancer treatment, Cancer 47 (1981), 207-214. (Pubitemid 11167383)
23. P. Esper, M.F. Chodak, G.M. Sinner, D. Cella and K.J. Pienta, Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument, Urology 50 (1997), 920-928. (Pubitemid 28021111)
24. M.A. Eisenberger and M. Carducci, Treatment of hormone refractory prostate cancer, in: Campbell-Walsh Urology, (9th ed.), (Vol III.), Chapter 105. Saunder, 2007, pp. 3101-3117.
25. P.A. di Sant'Agnese, Neuroendocrine differentiation in human prostatic carcinoma, Hum Pathol 23 (1992), 287-296.
26. G. Steineck, V. Reuter, W.K. Kelly et al., Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements, Acta Oncol 41 (2002), 668-674. (Pubitemid 36106212)
27. Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, A. Bossi and K. Fizazi, Combining carboplatin and etoposide in docetaxel pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features, Ann Oncol 20 (2009), 703-708.
28. I.F. Tannock, D. Osoba, M.R. Stockler et al., Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol 14 (1996), 1756-1764. (Pubitemid 26185452)